You are here

Generic Version of Cipro Approved

TEL AVIV, June 10 (Reuters) - Israeli drug maker Teva Pharmaceutical Industries (NasdaqNM:TEVA - News) has received approval from the U.S. Food and Drug Administration for Ciprofloxacin Tablets in strengths of 250, 500 and 750 mg, it said on Thursday.

The tablets are the generic equivalent of Bayer's (XETRA:BAYG.DE - News) antibiotic Cipro Tablets. Annual sales of the tablets, including those of the brand product and a product sold under licensing agreement with the originator, are about $1 billion.

Teva (Tel Aviv:TEVA.TA - News), the world's biggest generic drug maker, said shipment of the product is expected to begin immediately.

Source: Teva Pharmaceuticals

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM